Skip to content
Black Week: 20% off everything, code BLACK

Search

What are you looking for?

Type at least 2 characters to see suggestions.

RAD-150 60 caps

RAD-150 60 caps

RAD-150 TLB (TLB-150 Benzoate / Testolone Benzoate) 10 mg × 60 capsules is a benzoic ester of the classic SARM RAD-140. Supplier descriptions call it a prodrug that releases RAD-140 after hydrolysis, but no peer-reviewed paper has shown this. Parent form characterized in preclinical models (Miller 2011, Jayaraman 2014, Yu 2017): high affinity for the androgen receptor, tissue-selective agonism, modulation of anabolic genes. HPLC purity ≥98%, MS Q-TOF, COA for each batch. Research Use Only reagent for AR signaling and prodrug kinetics – not for use in humans or animals. SARMs prohibited by WADA (S1.2).

47,99 €
With code BLACK: 38,39 € Lowest price in the 30 days before the discount: 47,99 €
Fast shipping
Free delivery from 350 €
Returns policy

RAD-150 TLB 10 mg 60 capsules - TLB-150 Benzoate

  • RAD-150 (TLB-150 Benzoate): the benzoate ester of RAD-140.
  • 10 mg per capsule; pack of 60 capsules.
  • Research Use Only reagent, not a medicinal product.

Chemical reagent intended exclusively for laboratory tests (Research Use Only). It is not a medicinal product, dietary supplement or food. It is not intended for use on humans or animals. Sales only to registered research units and laboratories.

RAD-150 (also known as TLB-150 or Testolone Benzoate) is a benzoic ester of the classic non-steroidal SARM RAD-140 (Testolone) – a derivative described as a prodrug: by design assumption it should release the active RAD-140 molecule after hydrolysis with plasma esterases. No peer-reviewed paper has confirmed this. From a chemical point of view, RAD-150 is a “masked” form: the hydroxyl group of RAD-140 has been esterified with benzoic acid, which increases the lipophilicity of the molecule and – in design theory – extends its half-life relative to native RAD-140.

RAD-140 as the parent compound was developed by Radius Health in preclinical work on sarcopenia (muscle wasting) and hormone-dependent breast cancer (ER+/AR+) – the primary molecular characterization was published in Miller et al. 2011 (ACS Med Chem Lett). TLB-150 is the commercial and research name of a benzoate variant that appeared on the market for research chemicals a few years later as an attempt to obtain a more favorable pharmacokinetic profile of the oral form of SARM.

This reagent is supplied in a 60 capsules of 10 mg RAD-150 (TLB-150 Benzoate) — form adapted to studies of oral bioavailability, ester hydrolysis kinetics and exposure protocols in in vivo models. Purity verified by HPLC ≥98%, identity confirmed by mass spectrometry, COA available for each batch.

Regulatory status 

RAD-150 (TLB-150) is a derivative of RAD-140, which has not completed any phase of clinical trials resulting in registration — RAD-140 stopped at the stage of early preclinical studies and limited early phase studies, without registration as a drug. RAD-150 itself as a separate ester has not been the subject of published human clinical trials.

No registration as a drug with the EMA, FDA or anywhere in the world. It is not authorised in the EU as an ingredient of dietary supplements. SARMs have been on the WADA prohibited list (category S1.2 – Other Anabolic Agents) since 2008. Communicating the product as an “oral anabolic”, “muscle gainer” or “safer alternative to steroids” is contrary to the Research Use Only framework.

What are SARMs and tissue-selective profile

SARMs (Selective Androgen Receptor Modulators) are a class of non-steroidal compounds that bind to the androgen receptor (AR) and modulate its transcriptional activity in a manner tissue dependent. The concept arose from work on AR ligands that would recreate the beneficial anabolic profile of testosterone in muscles and bones, while limiting undesirable androgenic effects in tissues such as the prostate, skin or hair follicles.

RAD-150 ranks in the catalog Anabolic SARMs for muscle mass a special position because it is an ester of the parent form, described as its prodrug, and not a separate pharmacophore. Mechanistically, the tissue selectivity of SARMs results from several molecular phenomena:

  • Receptor conformation after ligand binding — non-steroidal SARMs stabilize the conformation of the AR ligand-binding domain different from that induced by testosterone or dihydrotestosterone (DHT), which translates into a differential set of recruited coactivators and corepressors
  • Tissue-specific expression of transcription cofactors — the same ligand-AR complex activates different gene programs depending on the repertoire of accessory proteins available in a given tissue
  • No metabolic conversion to stronger androgens — unlike testosterone, which is subject to 5α-reduction to DHT (a highly active androgen in the prostate and skin), non-steroidal SARMs are not substrates of 5α-reductase or aromatase
  • Tissue-dependent partial vs. full agonism — in skeletal muscle and bone, SARMs act as (close to) full AR agonists, while in the prostate they behave as partial agonists/antagonists

The classic, best characterized non-steroidal SARMs include RAD-140 (Testolone), LGD-4033 (Ligandrol), MK-2866 (Ostarine/Enobosarm), S-23, S-4 (Andarine) and YK-11 (a compound with a separate, steroid-like myostatin skeleton). The RAD-150 occupies a special position in this catalog – it is a RAD-140 ester described as a prodrug, i.e. by design assumption a transport form of the parent molecule, not a separate pharmacophore. The AR pharmacology world is watching RAD-140 and its derivatives for three reasons.

First, as a research tool tissue-selective androgen signaling — RAD-140 has one of the most anabolic-selective profiles in the class. Secondly, as a compound with documented effects (in rodent models). neuroprotective — a direction initiated by the work of Jayaraman et al. 2014. Third, as a ligand studied in context hormone-dependent breast cancer (ER+/AR+) —Yu et al. 2017 described the inhibition of the growth of cancer lines by activating AR as an antagonistic mechanism against estrogen signaling.

What is RAD-150 / TLB-150?

Chemically, RAD-150 is RAD-140 benzoic ester – a derivative of the parent molecule’s hydroxyl group, described as a prodrug.

  • Common name: RAD-150, TLB-150, Testolone Benzoate
  • Synonyms: TLB-150 Benzoate, RAD-140 benzoic ester
  • Relationship to the parent compound: benzoate ester of RAD-140 (Testolone); by design assumption it should release active RAD-140 after hydrolysis with plasma esterases
  • Pharmacological class: non-steroidal SARM (selective androgen receptor modulator) – assumed prodrug form
  • CAS number: 1208070-53-4 (PubChem CID 68547459; in case of uncertainty – “to be verified in the batch COA”)
  • Molar mass: 497.9 g/mol, C27H20ClN5O3 (PubChem; to be verified in the batch COA)
  • Delivered form: HPMC hard capsule, 10 mg of active substance per capsule, 60 capsules; pharmaceutical grade ≥98% HPLC

Origin: RAD-140 (Testolone) was developed by the company Radius Health as a candidate compound with anabolic selectivity for muscles and bones – the original design, synthetic and preclinical characterization appeared in the work of Miller et al. 2011 (ACS Med Chem Lett). The program included indications for muscle atrophy (sarcopenia, cancer cachexia) and hormone-dependent breast cancer.

TLB-150 Benzoate is an ester of RAD-140, which appeared in the market of research chemicals as an attempt to obtain more favorable oral pharmacokinetics – the benzoic ester is supposed to protect the molecule from part of the first-pass metabolism and release RAD-140 gradually as a result of enzymatic hydrolysis.

Table of physicochemical characteristics

Parameter Value
Common name RAD-150 / TLB-150 / Testolone Benzoate
Class Non-steroidal SARM – benzoate ester of RAD-140
Active form after hydrolysis (assumed) RAD-140 (Testolone)
CAS number 1208070-53-4 (PubChem CID 68547459; for COA verification)
Molar mass 497.9 g/mol (PubChem; to be verified in COA)
Chemical modification Esterification of the -OH group of RAD-140 with benzoic acid
Release mechanism (assumed) Hydrolysis with plasma esterases → RAD-140
Affinity of the active form (RAD-140) for AR Ki ~7 nM (Miller et al. 2011)
Supplied form HPMC capsule, 10 mg/caps, 60 capsules
Purity ≥98% HPLC
Identity confirmation MS Q-TOF

Mechanism of action at the molecular level

RAD-150 is described as a prodrug: by design assumption, the proper pharmacological activity should appear only after hydrolysis to RAD-140. Data on the ester itself come down to one figure from a patent (below). The mechanism can be described in five axes, the last of which refers directly to the prodrug strategy. Pharmacological profile observed in preclinical models (active form of RAD-140):

  1. Selective androgen receptor (AR) agonism — RAD-140 binds to the ligand-binding domain of the androgen receptor with high affinity (Ki ~7 nM according to Miller et al. 2011). Ligand binding stabilizes the receptor conformation activating nuclear translocation and binding to androgen response elements (AREs) in the promoters of target genes
  2. Tissue-selective agonism — in skeletal muscle and bone, RAD-140 behaves as a (close to) full AR agonist, while in the prostate it shows a partial agonist/antagonist profile. In preclinical models, this resulted in an increase in lean body mass with a limited effect on prostate mass relative to testosterone.
  3. Transcription of anabolic genes — AR activation by RAD-140 modulates the expression of genes related to muscle anabolism, including pathways IGF-1 (insulin-like growth factor) and factors regulating myogenic differentiation (including MyoD); the effect is increased muscle protein synthesis in cellular and animal models
  4. Neuroprotection in rodent models —Jayaraman et al. 2014 showed that RAD-140 protected neurons from degeneration in a rat model with kainate lesion; AR activation in nervous tissue triggered survival pathways independent of conversion to estrogen (a mechanism separate from estrogen neuroprotection)
  5. Prodrug strategy (RAD-150 specific axis) — benzoic ester masks the hydroxyl group of RAD-140, increasing the lipophilicity of the molecule. The design assumption is protection against part of the first-pass metabolism in the liver and gradual release of active RAD-140 as a result of hydrolysis with plasma esterases – which theoretically extends the half-life and smoothes the exposure profile over time.

Pharmacokinetic profile (based on design assumptions and data for RAD-140): the points below are design assumptions for the ester. No peer-reviewed paper has been published on the hydrolysis of RAD-150, its half-life or androgen receptor binding by the ester itself; the only figure, an IC50 of 130 nM in a rat androgen receptor binding assay, comes from the Radius Health patent (US 8629167, compound 87), not from a publication.

  • Benzoic ester hydrolysis: plasma esterases → RAD-140 release (kinetics not publicly characterized)
  • Lipophilicity: increased compared to RAD-140 (esterification effect)
  • Half-life: assumed to be longer than RAD-140; human data unavailable
  • Oral bioavailability in humans: unknown — no published phase I studies for RAD-150
  • Metabolism of the active form: hepatic (RAD-140 is subject to oxidative metabolism); full profile uncharacterized

RAD-150 in the SARM class – pharmacological position: In the catalog of non-steroidal AR modulators, RAD-150 occupies a position different from the other members of the group:

  • RAD-140 (Testolone) — native form, one of the most anabolic-selective SARMs; parent compound RAD-150
  • LGD-4033 (Ligandrol) — high affinity for AR, anabolic profile; subject of early safety research (reagent LGD-4033 Ligandrol)
  • MK-2866 (Ostarine) — one of the best-studied SARMs in early clinical phases for sarcopenia
  • YK-11 — a compound with a steroid-like skeleton, studied in the context of myostatin modulation — a separate mechanism from classic SARMs (reagent YK-11)
  • RAD-150 (TLB-150) — benzoate ester of RAD-140, described as a prodrug; by design assumption a transport form of the parent molecule with more favorable oral kinetics, with no data to confirm it

Applications in scientific research

No peer-reviewed papers on RAD-150 have been published, so the areas below are possible research directions, not a description of existing literature: ester hydrolysis kinetics, receptor affinity and transcriptional activity in in vitro models (cell lines expressing AR, hepatocytes, plasma), and anabolic markers of skeletal muscle in animal models. Specific research directions include:

  • Pharmacology of tissue-selective AR signaling — characterization of the agonist profile of RAD-140 in muscle vs. prostate, mapping of recruited transcription cofactors
  • Kinetics of prodrug hydrolysis — studies of the release rate of RAD-140 from benzoic ester in the presence of plasma and tissue esterases, comparison of exposure profiles of RAD-150 vs. RAD-140
  • Models of muscle anabolism — effect on protein synthesis, IGF-1 and MyoD pathways, lean body mass in rodent models
  • Neuroprotective studies — continuation of the direction of Jayaraman et al. 2014 on the role of AR activation in neuronal survival in CNS injury models
  • Molecular oncology (ER+/AR+) — research on AR activation as a mechanism of inhibiting estrogen signaling in breast cancer lines (directed by Yu et al. 2017)

Comparison of the profiles of individual compounds and the criteria for selecting a SARM for a specific research purpose (mass, reduction, recomposition) are discussed in more detail in the guide. SARMs for bodybuilders.

REGULATORY STATUS

SARMs, including RAD-140 and its derivatives, are found on WADA Prohibited List in category S1.2 (Other Anabolic Agents – SARMs) since 2008 — prohibited substances constantly (both during and outside the launch period). The identification of RAD-140 and its metabolites in anti-doping protocols is well developed, and if RAD-150 hydrolyzes to RAD-140, the same parent molecule is what will be detected.

RAD-140 was also an item FDA warnings (Warning Letters) directed to distributors selling SARMs as supplements. It has also been described in the literature cases of hepatotoxicity associated with human use of RAD-140 outside the research setting (case reports). Registered athletes (ADAMS) must check the current list of prohibited substances before making any decision. Not registered as a drug in the EU or the USA.

Summary

RAD-150 (TLB-150 Benzoate, Testolone Benzoate) is a benzoic ester of the classic non-steroidal SARM RAD-140 – a derivative described as a prodrug: by design assumption it should release active RAD-140 after hydrolysis with plasma esterases and act for longer. No publications confirm this. The parent form of RAD-140, developed by Radius Health (Miller et al. 2011), in preclinical models shows high affinity for the androgen receptor (Ki ~7 nM), tissue-selective agonism (full in muscle/bone, partial in the prostate), modulation of anabolic genes (IGF-1, MyoD), neuroprotective profile in rodent models (Jayaraman et al. 2014) and activity in hormone-dependent ER+/AR+ breast cancer (Yu et al. 2017).

Form 60 capsules of 10 mg, HPLC purity ≥98%, MS Q-TOF, COA for each batch. Regulatory Status – Research Use Only; lack of registration as a medicine; SARMs permanently banned by WADA (S1.2) since 2008; cases of RAD-140 hepatotoxicity outside the research framework have been reported.

Bibliography

  1. Jayaraman A, Christensen A, Moser VA, Vest RS, Miller CP, Hattersley G, et al. (2014). Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats. PubMed
  2. Miller CP, Shomali M, Lyttle CR, O’Dea LS, Herendeen H, Gallacher K, et al. (2011). Design, synthesis, and preclinical characterization of the selective androgen receptor modulator (SARM) RAD140. PubMed
  3. Yu Z, He S, Wang D, Patel HK, Miller CP, Brown JL, et al. (2017). Selective androgen receptor modulator RAD140 inhibits the growth of androgen/estrogen receptor-positive breast cancer models with a distinct mechanism of action. PubMed
  4. Solomon ZJ, Mirabal JR, Mazur DJ, Kohn TP, Lipshultz LI, Pastuszak AW (2019). Selective androgen receptor modulators: current knowledge and clinical applications. PubMed
  5. Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT (2008). Selective androgen receptor modulators in preclinical and clinical development. PubMed